A pioneering music therapy programme embedded within NHS mental health dementia wards has demonstrated feasibility and acceptability in a groundbreaking study that could transform care for some of the most vulnerable patients in the health system. The MELODIC intervention achieved high treatment adherence rates while showing no increase in distress symptoms or safety incidents.
A landmark international collaboration has created one of the world’s largest protein datasets, analysing 250 million protein measurements from over 35,000 biofluid samples to identify novel biomarkers for Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative conditions that affect 57 million people globally.
A groundbreaking stem cell repository has been established using blood samples from over 100 individuals selected for their extreme genetic risk profiles for Alzheimer’s disease. The IPMAR resource will enable researchers worldwide to study how genetic variants contribute to the neurodegenerative condition in laboratory models.
Researchers from the VIB-KU Leuven Center for Brain & Disease Research have unveiled a predictive model that could revolutionise Alzheimer’s disease diagnosis and treatment strategies. Their study, published in Molecular Neurodegeneration, reveals how specific genetic mutations in three causal genes create a ‘molecular clock’ that accurately forecasts disease onset, potentially enabling clinicians to provide personalised […]
New research published in Nature Reviews Neurology reveals that dementia will become the world’s third leading cause of death by 2040, surpassed only by ischaemic heart disease and stroke, yet continues to be overlooked in major health policy frameworks and resource allocation.
The first comprehensive US diagnostic guidelines in two decades establish standardised evaluation process across primary and specialty care settings, emphasising a patient-centred approach and integration of emerging biomarkers.
New research from CUNY identifies how brain immune cells drive neurodegeneration through stress-induced toxic lipid production, offering potential therapeutic targets.
A new investigation of FDA-approved Alzheimer’s drug donanemab highlights concerns about excess deaths, missing safety data, and financial conflicts of interest among FDA advisory panel members who recommended approval.
A new book by gerontologist Dr Macie Smith aims to provide essential guidance for those caring for loved ones with dementia. The 60-page resource, titled “A Dementia Caregiver Called to Action: The Journey”, addresses common questions and offers insights throughout the caregiving process.
Cambridge scientists question whether recently approved amyloid immunotherapy treatments for Alzheimer’s disease will significantly reduce the condition’s burden, citing concerns about efficacy, safety, and health system challenges.
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@interhospi.com
PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.
Anna Flury